Novartis investigative site

Durham, North Carolina 27710

0 studies enrolling now · 40 studies all time

What they study most

Acute Heart Failure, Acute Leukaemia, Acute Myocardial Infarction, Advanced/ Metastatic Renal Cell Cancer, Allergic Asthma, Alzheimers Disease, Bullous Pemphigoid, Cancer, Carcinoma, Renal Cell, Chronic Heart Failure, Chronic Kidney Disease (CKD), Chronic Myelogenous Leukemia

Studies at this site

• Study of Efficacy, Safety, Tolerability, Pharmacokinetic (PK) and Pharmacodynamic (PD) of an Anti-CD40 Monoclonal Antibody, CFZ533, in Kidney Transplant Recipients — Completed
• Study of Pharmacodynamics, Pharmacokinetics, Safety and Tolerability of VAY736 in Patients With Idiopathic Pulmonary Fibrosis — Stopped early
• Prospective ARNI vs ACE Inhibitor Trial to DetermIne Superiority in Reducing Heart Failure Events After MI — Completed
• Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis — Completed
• Safety Study in Patients With Multiple Sclerosis Treated Fingolimod or Other Approved Disease-modifying Therapies — Completed
• A Study of CNP520 Versus Placebo in Participants at Risk for the Onset of Clinical Symptoms of Alzheimer's Disease — Stopped early
• Long-term Safety and Tolerability of 0.5 mg Fingolimod in Patients With Relapsing Forms of Multiple Sclerosis — Completed
• Dabrafenib Plus Trametinib vs Vemurafenib Alone in Unresectable or Metastatic BRAF V600E/K Cutaneous Melanoma — Completed
• Efficacy and Safety Study of CSJ148 in Stem Cell Transplant Patients — Completed
• A Placebo- and Paroxetine-controlled Study of the Efficacy, Safety and Tolerability of Agomelatine (25 or 50 mg) in the Treatment of Major Depressive Disorder (MDD) — Completed
• A Phase I/II Study to Assess the Safety and Efficacy of TKI258 for the Treatment of Refractory Advanced/Metastatic Renal Cell Cancer — Completed
• SD, IL-13 Production Rate in IPF — Completed
• Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF) — Stopped early
• Safety and Efficacy of Multiple Daily Dosing of Oral LFF571 in Patients With Moderate Clostridium Difficile Infections — Completed
• A Dose Finding Study With I.V. Panobinostat (LBH589), Docetaxel, and Prednisone in Patients With Hormone Refractory Prostate Cancer — Completed
• A Study to Evaluate Pazopanib as an Adjuvant Treatment for Localized Renal Cell Carcinoma (RCC) — Completed
• Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma — Completed
• A Safety and Efficacy Study of Eltrombopag in Subjects With AML — Completed
• A Facilitated Access Program to Provide Everolimus (RAD) Maintenance for Patients Completing Therapy in RAD Trials in Solid Organ Transplantation — NO_LONGER_AVAILABLE
• Ofatumumab Maintenance Treatment vs No Further Treatment in Relapsed CLL Responding to Induction Therapy — Stopped early
• Study of Secukinumab Compared to Ustekinumab in Subjects With Plaque Psoriasis — Completed
• Lapatinib Plus Capecitabine Versus Trastuzumab Plus Capecitabine in ErbB2 (HER2) Positive Metastatic Breast Cancer — Completed
• Study To Assess Long Term Safety Of Pazopanib — Completed
• Advancing Renal TRANSplant eFficacy and Safety Outcomes With an eveRolimus-based regiMen (TRANSFORM) — Completed
• Extension Study to Evaluate the Long-term Efficacy and Safety of Everolimus in Liver Transplant Recipients — Completed
• Efficacy, Safety and Tolerability of Serelaxin When Added to Standard Therapy in AHF — Completed
• Continuation Study of Lapatinib Monotherapy or Lapatinib in Combination With Other Anti-cancer Agents — Completed
• Safety and Efficacy of AIN457 in Noninfectious Uveitis — Completed
• This Was an Open-label, Single-arm Extension Study (CFTY720D2306E1) to a Double-blind, Randomized Multicenter, Placebo-controlled, Parallel-group Core Study (CFTY720D2306) in PPMS. — Stopped early
• Efficacy at 24 Weeks and Safety, Tolerability and Long Term Efficacy up to 2 Years of Secukinumab (AIN457) in Patients With Active Rheumatoid Arthritis and an Inadequate Response to Anti-TNFα Agents — Completed
• Efficacy and Safety of Aliskiren and Aliskiren/Enalapril Combination on Morbidity-mortality in Patients With Chronic Heart Failure — Completed
• Safety, Efficacy and PK/PD of QGE031 vs. Placebo in Patients With Active Bullous Pemphigoid Despite Oral Steroid Treatment — Stopped early
• Imatinib (QTI571) in Pulmonary Arterial Hypertension — Completed
• Non-inferiority Study of Safety and Efficacy of Everolimus With Low Dose Tacrolimus to Mycophenolate Mofetil With Standard Dose Tacrolimus in Kidney Transplant Recipients — Completed
• Extension to QTI571A2301 to Evaluate the Long-term Safety, Tolerability and Efficacy of Imatinib in Severe Pulmonary Arterial Hypertension (PAH) — Stopped early
• Safety and Efficacy of Imatinib Versus Interferon-α Plus Cytarabine in Patients With Newly Diagnosed Philadelphia Chromosome Positive Chronic Myelogenous Leukemia — Completed
• Efficacy and Safety of Concentration-controlled Everolimus to Eliminate or to Reduce Tacrolimus Compared to Tacrolimus in de Novo Liver Transplant Recipients — Completed
• Efficacy of Omalizumab in Adults (18-60 Years of Age) With Moderate-Severe, Persistent Allergic Asthma, Despite Receiving Inhaled Corticosteroids and Long Acting Beta-agonists — Completed
• RAD001 Plus Best Supportive Care (BSC) Versus BSC Plus Placebo in Patients With Metastatic Carcinoma of the Kidney Which Has Progressed After Treatment With Sorafenib and/or Sunitinib — Completed
• Safety and Efficacy Trial With Zoledronic Acid for the Treatment of Paget's Disease of Bone, Including an Extended Observation Period — Completed